We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) holds a strong position in the multiple sclerosis (“MS”) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. However, as competition in the MS market intensifies, Biogen is trying to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.
Biogen’s earnings performance has been decent so far. The company delivered a positive surprise in three of the last four quarters. The average earnings beat over the last four quarters is 5.13%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s third quarter 2018 earnings beat expectations. The company posted earnings of $7.40 per share while our consensus called for EPS of $6.80.
Revenues Beat: Biogen posted revenues of $3.44 billion, beating the consensus estimate of $3.33 billion. Revenue increased 12% year over year.
Key Statistics: The company's oral MS drug Tecfidera’s sales rose 2% year over year to $1.09 billion. The other MS drug, Tysabri’s sales were flat year over year at $470 million. Spinraza (spinal muscular atrophy) sales grew 73% year over year and 11% sequentially to $468 million driven by sales growth in both United States and in ex U.S. markets.
Pre-Market Trading: Shares were in-active in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) holds a strong position in the multiple sclerosis (“MS”) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. However, as competition in the MS market intensifies, Biogen is trying to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.
Biogen’s earnings performance has been decent so far. The company delivered a positive surprise in three of the last four quarters. The average earnings beat over the last four quarters is 5.13%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s third quarter 2018 earnings beat expectations. The company posted earnings of $7.40 per share while our consensus called for EPS of $6.80.
Revenues Beat: Biogen posted revenues of $3.44 billion, beating the consensus estimate of $3.33 billion. Revenue increased 12% year over year.
Key Statistics: The company's oral MS drug Tecfidera’s sales rose 2% year over year to $1.09 billion. The other MS drug, Tysabri’s sales were flat year over year at $470 million. Spinraza (spinal muscular atrophy) sales grew 73% year over year and 11% sequentially to $468 million driven by sales growth in both United States and in ex U.S. markets.
Pre-Market Trading: Shares were in-active in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Biogen Inc. Price and Consensus
Biogen Inc. Price and Consensus | Biogen Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>s